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Increased endothelin-1 expression in the kidney in hypercalce- The impaired urinary concentrating capacity in hyper-
mic rats. calcemic patients has been well-known for several de-
Background. Although hypercalcemia causes diuresis and cades. Urinary concentrating defects and polyuria are thenatriuresis, the molecular mechanisms of these effects are not
most important renal manifestations of hypercalcemia andwell established. Recently, the important role of the calcium-
the dehydration caused by hypercalcemia may furthersensing receptor (CaR) in hypercalcemia-induced polyuria was
reported. Endothelin-1 (ET-1) that is locally produced in the exacerbate the hypercalcemic state, sometimes leading
nephron has been suggested to have the natriuretic and/or to hypercalcemic crisis [1–6]. Several mechanisms by
diuretic effects in the kidney. Therefore, we hypothesized that which hypercalcemia induces polyuria have been demon-ET-1 expression could be increased through the activation of
strated. DiBona [7] reported that hypercalcemia leadsCaR in the kidney in hypercalcemia.
to a reduction in fractional and absolute reabsorption ofMethods. Rats were made hypercalcemic by dihydrotachys-
terol (DHT) treatment. The urinary concentration of ET-1 and Na in the proximal tubule. Suki et al [8] showed that
the mRNA expression of ET-1 in the kidney were determined. hypercalcemia inhibits the absorption of Na as well as
Immunohistochemistry was performed to determine types of
Ca2 and Mg2 in both cortical thick ascending limb ofthe cells that produce ET-1. CaR and ET-1 promoter luciferase
Henle (CTAL) and medullary thick ascending limb ofconstructs were co-expressed in COS-7 cells and the ET-1 pro-
moter activity following the addition of extracellular calcium Henle (MTAL). Most important, hypercalcemia was
was measured by the luciferase assay. shown to inhibit vasopressin (AVP)-induced cyclic aden-
Results. In hypercalcemic rat, urinary ET-1 excretion was osine monophosphate (cAMP) production and to block
increased by twofold, and ET-1 mRNA expression was in-
subsequent AVP-induced Na and water reabsorptioncreased in the kidney cortex by threefold. In cortical collecting
in the cortical collecting duct (CCD) and the inner med-duct (CCD), both principal cells and intercalated cells synthe-
sized ET-1. In cells that express CaR, ET-1 promoter was ullary collecting duct (IMCD) [9–12].
activated in a dose-dependent manner by extracellular calcium Endothelin-1 (ET-1), a potent vasoconstrictor peptide,
over the range of 0.5 to 3.0 mmol/L. has been shown to have a diuretic and natriuretic effectConclusions. First, activation of CaR increases ET-1 tran-
in the kidney. Recent reports demonstrate that the kid-scription in a dose-dependent manner. Second, hypercalcemia
ney is an important site for ET-1 synthesis and secretion,increases ET-1 production in the kidney cortex. These data
suggest the possibility that CaR might play an important role and that ET-1 plays a key role in the tubular function
in hypercalcemia-induced increase in ET-1 production. of the kidney in an autocrine/paracrine manner (reviewed
in [13–17]). The mechanisms by which ET-1 induces na-
triuresis/diuresis in the kidney have been elucidated by
several laboratories, including our own. ET-1 inhibits
the AVP-induced increase in cAMP accumulation in the
CCD and IMCD, resulting in the inhibition of AVP-
induced water reabsorption [18–21]. These natriureticKey words: hypercalcemia, polyuria, endothelin, calcium-sensing re-
ceptor. and diuretic effects of ET-1 are mediated by the endo-
thelin receptor B (ETB) [22–25].Received for publication October 1, 2001
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range. CaR activates a number of intracellular signaling calcium, phosphate, and ET-1 concentrations. Kidneys
were also harvested at the end of the experiments forsystems that have effects on the physiologic responses
to alterations in the extracellular calcium. Patients with isolation of total RNAs and for immunohistochemistry.
familial hypocalciuric hypercalcemia that results from
ET-1 concentration measurementthe loss of function mutations in the CaR achieve essen-
tially normal maximal urinary concentration even in the Plasma and urinary ET-1 were extracted using C18
column (Waters, Millipore Corporation, Milford, MA,presence of hypercalcemia, while patients with hypercal-
cemia as a result of other causes commonly develop a USA) and their concentrations were determined by ra-
dioimmunoassay, as described previously [30].defect in the urine concentration ability (reviewed in
[26]). These observations suggest an important role of
RNA extraction and competitive RT-PCRthe CaR-dependent signaling system in the hypercalce-
mia-induced polyuria. Isolation of the cDNA clone for Rats were sacrificed at the end of the experiment and
total RNA was extracted from rat kidney cortex andthe CaR revealed that it belongs to the G protein–
coupled receptor family [27]. CaR is shown to activate medulla using TRIZOL Reagent (Gibco BRL, Rockville,
MD, USA) following the manufacturer’s instructions. ToGq-coupled signaling pathway [28]. Since ET-1 produc-
tion is stimulated by Gq-coupled signaling pathway [29], determine the mRNA levels of ET-1, competitive reverse
transcription-polymerase chain reaction (RT-PCR) assaywe hypothesized that the hypercalcemia could induce
the production of ET-1 through the activation of CaR in was performed using RNA competitors. Each sample of
total RNA (1g) was simultaneously reverse transcribedthe kidney, and that the increase in the ET-1 production
might play a role in the hypercalcemia-induced polyuria. with serial dilutions of RNA competitor generated by
in vitro transcription from the plasmid containing theThe aim of the present study is to determine if hyper-
calcemia stimulates ET-1 production in the kidney and deletion mutant cDNA sequence. The deletion mutant
cDNA was synthesized by in vitro overlap extensionif the activation of CaR increases the transcription of
ET-1 mRNA. In the current study, we found a twofold PCR as described previously [31]. The inner antisense
primer and the inner sense primer were designed toincrease in urinary ET-1 excretion and a threefold in-
crease in ET-1 mRNA expression in the kidney cortex anneal with the rat preproET-1 cDNA [32] and to have
the 5 tail complementary to the annealing site of theof hypercalcemic rats. An increase in ET-1 synthesis in
kidney cortex tubules was also observed in the immuno- inner sense primer or the inner antisense primer, respec-
tively. The sequence of the inner antisense primer andhistochemical studies. Furthermore, we demonstrated
that activation of the wild-type CaR, but not its inactive the inner sense primer were 5-GTCTGCTTGGCCTA
GTCCATACGGGACGAC-3 and 5-ATGGACTAGGmutant, R796W, increased human ET-1 promoter activ-
ity in a dose-dependent manner in cultured cells. These CCAAGCAGACAAAGAACTCC-3, respectively. The
sequence of the outer sense and outer antisense primersresults indicate that hypercalcemia increases ET-1 pro-
duction in the kidney cortex and suggest the possibility were 5-GGATTATTTTCCCGTGATCTTCTC-3 and
5-GGCTCTGTAGTCAATGTGCTCG-3, respectively.that hypercalcemia induces ET-1 production through the
activation of CaR. The deletion mutant PCR fragment, which lacks 114 bp
internal sequences, was subcloned into pGEM-T easy
vector (Promega, Madison, WI, USA) and the sequence
METHODS
was confirmed by the dideoxy chain termination method
Animal experiments using fluorescent dye-labeled terminators on an auto-
matic sequencer (ABI model 310; Applied Biosystems,Experiments were conducted in male Wistar rats (160
180 g) from Kyudo Laboratories (Fukuoka, Japan). Inc., Foster City, CA, USA). The cRNA competitor was
synthesized from the deletion mutant plasmid using anThese rats were divided into two groups: (1) hypercalce-
mic rat group (N  8) in which rats received 4.25 mg/kg mCAP RNA Capping Kit (Stratagene, La Jolla, CA,
USA) following the manufacturer’s instruction andbody weight of dihydrotachysterol (DHT) (Sigma Chem-
icial Co., St. Louis, MO, USA) with commercial rat chow cRNAs were purified using RNaid Kit (Bio101, Inc.,
Vista, CA, USA). RT-competitive PCR was performed(MF; Oriental Yeast Co., Ltd., Tokyo, Japan) and (2)
control rat group (N  8) fed with commercial rat chow. by adding seven to eight serial dilutions of RNA competi-
tor to 1 g of each RNA sample and resolved on 1.5%All rats were allowed free access to water and the amount
of food and water consumed was measured every 24 agarose gels stained with ethidium bromide. The densi-
ties of the 617 bp PCR product from sample RNA andhours. All rats were kept in metabolic cages during the
entire experiment, and urine samples were collected and the 503 bp PCR product from RNA competitor were
quantitated by densitometry (Densitograph 4.0; ATTO,stored at70C. Urinary ET-1 concentrations were mea-
sured in the 24-hour urine samples. Blood samples were Tokyo, Japan).
Log-log scale plots of the ratio of fluorescence inten-obtained at the end of the experiments to measure serum
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ized using horseradish peroxidase (HRP)-coupled don-
key antirabbit antibody (Amersham Pharmacia Biotech,
Buckinghamshire, England, UK) and 3,3-diaminobenzi-
dine (DAB).
Plasmids
The cDNAs for the wild-type human CaR and its
inactive mutant, R796W, both in pcDNA3 vector (In-
vitrogen, Carlsbad, CA, USA) [35], were generous gifts
from Dr. Edward M. Brown and Dr. Mai Bai (Harvard
Medical School, Boston, MA, USA). The 2.4 kb human
ET-1 5-flanking region [36] was a kind gift from Dr.
Gary A. Visner (University of Florida, Gainesville, FL,
USA). A –2293 bp to 166 bp ET-1 5 flanking region
fragment was cut out and subcloned into pGL3/basic
vector (Promega), which contains firefly (Photinus pyr-
Fig. 1. Quantification of endothelin-1 (ET-1) mRNA by competitive alis) luciferase gene as a reporter.reverse transcription-polymerase chain reaction (RT-PCR). (A ) A rep-
resentative ethidium bromide-stained gel for competitive RT-PCR anal-
ysis. The upper bands (607 bp) are the target template PCR products Cell culture, transfection, and luciferase assay
and the lower bands (503 bp) are the competitive template PCR product.
COS-7 cells were purchased from American Type Cul-The amount of RNA competitor added in each reaction was 0.25, 0.5,
1, 2, 4, 8, 16 amol/L from left to right, respectively. (B ) Log-log plot ture Collection (Rockville, MD, USA). Cells were main-
of the ratio of quantitative fluorescence data versus initial amount of tained in Dulbecco’s modified Eagle’s medium (DMEM)RNA competitor (amol/L).
(Gibco BRL) supplemented with 10% fetal bovine se-
rum (FBS) in a humidified incubator at 37C and 5%
carbon dioxide (CO2). COS-7 cells were grown to 100%
sity of target to competitor versus the known amount of confluence in six-wells plates and transfected by diethyl-
RNA competitor added in the replicate reaction were aminoethyl (DEAE)-dextran method [37]. Briefly, cells
linear. To correct for differences in molecular weight, were incubated with the transfection mixture containing
fluorescence data obtained from competitive templates plasmid DNAs, 100 g/mL DEAE-dextran (Amersham
were multiplied by 617/503. At the point where target Pharmacia Biotech), and 100mol/L chroloquine (Sigma)
and competitive PCR products were equivalent, the in serum-free DMEM. After 2 hours incubation at 37C,
amount of target (ET-1) mRNA present in the initial the media were aspirated, and prewarmed 10% dimethyl
sample was equal to the known starting amount of the sulfoxide (DMSO) was added to the cells for 2 minutes.
competitive template. Experiments were eliminated from Immediately, the cells were washed with phosphate-buf-
further analysis if the correlation of fit (r2) for the gener- fered saline (PBS), incubated with DMEM containing
ated curve was 0.9. Figure 1 illustrates a representative 10% FBS for 16 hours, and then stimulated with DMEM
experiment. Addition of increasing amounts, from 0.25 containing various concentrations of calcium for 48 hours.
to 16 amol, of the competitive RNA template to replicate After stimulation, the cells were washed twice with ice-
reactions containing 1 g of rat kidney RNA resulted
cold PBS and used for luciferase assay. Luciferase assay
in a progressive increase in the competitive template
was performed with Luciferase Assay System (Promega)PCR product (503 bp, lower band) and a corresponding
following manufacturer’s instruction using Luminometerprogressive decrease of the target template PCR product
TD-20/20 (Turner Designs, Sunnyvale, CA, USA). The(617 bp, upper band).
protein concentration of each sample was determined
by BCA Protein Assay Kit (Pierce, Rockford, IL, USA)Immunohistochemistry
and the values for luciferase activity were expressed inKidneys were fixed by retrograde perfusion via aorta
relative light units (RLU).with buffered formalin. Removed kidneys were embed-
ded in paraffin. Serial paraffin sections were cut into
Statistical analysis2 m thickness and immunostained using procedures
Statistical significance was evaluated using the two-described previously [33]. Primary antibody for ET-1
tailed, unpaired Student t test for comparisons betweenwas obtained from Peninsula laboratories (Belmont, CA,
two means, or ANOVA analysis, followed by Newman-USA). Anti-aquaporin (AQP)-2 antibody [34] was a kind
Keuls method for more than two means. A value of P gift from Dr. Mark A. Knepper (National Institutes of
Health, Bethesda, MD, USA). Specimens were visual- 0.05 was regarded as statistically significant.
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Table 1. Plasma calcium, phosphate, and creatinine levels in
dihydrotachysterol-treated and control rats at day 5
Control DHT
Plasma calcium mg/dL 10.20.7 12.70.9a
Plasma phosphate mg/dL 8.40.9 8.41.2
Plasma creatinine mg/dL 0.220.05 0.240.03
Body weight g 35315 3348a
Values are expressed as meansSD; N  eight rats per group.
aP  0.01
RESULTS
Generation of hypercalcemic rat model
The present study is designed to investigate whether
renal ET-1 production is stimulated by hypercalcemia. Fig. 2. The ratio of urinary endothelin-1 (ET-1) excretion to urinary
creatinine excretion in control ( ) and hypercalcemic ( ) rats. ValuesTo generate hypercalcemic in vivo model, we treated
are expressed as means  SD; N  eight rats per group. *P  0.01,Wister rats with a vitamin D analogue, DHT. Wistar compared with control at each time point.
rats treated with dihydrotachysterol (DHT) for 5 days
developed hypercalcemia with a significant increase in
total plasma calcium (Table 1). There were no differ-
ences in plasma phosphate and creatinine concentrations
between control and hypercalcemic rats. Body weight of
DHT-treated rat was slightly lower than that of a control
rat on day 5.
Urinary and serum ET-1 levels in hypercalcemic rats
Previous observations that only negligible amounts of
labeled ET-1, which was infused into the systemic circula-
tion of normal rats, could be recovered in the urine [38],
and that no significant correlation was detected between
urinary ET-1 excretion and plasma ET-1 levels in various Fig. 3. Quantification of endothelin-1 (ET-1) mRNA in the renal cor-
tex and medulla of control and hypercalcemic (HC) rats. Values areconditions [39, 40] suggest that urinary ET-1 is derived
expressed as meansSD; N eight rats per group. *P 0.01, comparedmainly from the kidney. Therefore, urinary ET-1 excre-
with control.
tion is thought to reflect the amount of ET-1 produced
in the kidney. In order to determine whether locally
produced ET-1 in the kidney is increased in hypercalce-
mia, we measured the urinary excretion of ET-1 in the nary excretion of ET-1 in hypercalcemic rats is associated
with the increase in the mRNA expression. As shownDHT-treated and control rats. As shown in Figure 2,
urinary ET-1 excretion was increased progressively in in Figure 3, a substantial increase in ET-1 mRNA expres-
sion was observed in the cortex. Although the kidneythe hypercalcemic rats, but not in the control rats. The
significant increase (approximately 1.5-fold) in urinary medulla has higher basal expression level of ET-1 than
the kidney cortex, there was no significant change inET-1 could be observed on day 2 and an even greater
increase (approximately twofold) was observed on day 4 ET-1 expression associated with hypercalcemia.
in the hypercalcemic rats. There was no significant differ-
Immunohistochemistryence in urinary creatinine excretion between control and
hypercalcemic rats at any point. We also determined the To investigate which nephron segment is responsible for
the hypercalcemia-induced increase in ET-1 production,plasma ET-1 level to study the effect of hypercalcemia
on circulating endothelin levels. Interestingly, there was immunohistochemical experiment was performed. In the
cortex of control rats, endothelin signal was detectedno significant difference in the plasma ET-1 level be-
tween control and hypercalcemic rats (control 3.51  mainly in the CCD and distal tubules (Fig, 4A). Similar
staining was not observed in the kidney using the control0.61 pg/mL vs. hypercalcemia 3.53  0.56 pg/mL, NS).
unimmunized rabbit serum (data not shown). Consistent
ET-1 mRNA expression in hypercalcemic rats with a previous report [41], faint signal was observed in
the brush border of proximal tubules, which may indicateNext, we examined the expression level of ET-1
mRNA in the kidney to determine if the increased uri- the ET-1 uptake at this site. In the medulla of control
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Fig. 4. Immunohistochemical localization of endothlin-1 (ET-1) in the rat kidney. Renal cortex of control rats (A ) and hypercalcemic rats (B )
stained with anti-ET-1 antibody. Cortical collecting duct (asterisk in B) and distal tubules are stained. The border of inner stripe and inner medulla
of control rats (C ) and hypercalcemic rats (D ). Strong signal was observed in the vascular compartment of the inner medulla. Serial sections of
renal cortex of hypercalcemic rats, stained with anti-aquaporin-2 antibody (E ) or anti-ET-1 antibody (F ). Arrows indicated intercalated cells.
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Fig. 5. Dose-dependent stimulation of hu-
man endothelin-1 (ET-1) promoter activity by
extracellular calcium in wild-type calcium-
sensing receptor (CaR) transfected cells. Val-
ues are expressed as means  SD; N  6 for
each experiment. Abbreviations are: W, wild-
type; M, loss of function mutant; RLU, rela-
tive light units. *P  0.05 and **P  0.01,
compared with 0.5 mmol/L calcium (Ca) con-
dition.
rats, strong signal was detected in the vascular compart- DISCUSSION
ment (Fig. 4C). In hypercalcemic rats (Fig. 4B and D), Until this report, the regulation of ET-1 production
ET-1 signal in CCD was slightly increased compared has not been studied in any organ (including serum and
with control rats, whereas no significant change in ET-1 urine) in hypercalcemia. In the current study, we demon-
staining was observed in the medulla. To identify which strated that hypercalcemia increases ET-1 in the kidney
cells in the CCD produce ET-1, serial section staining at the mRNA and protein levels. In addition, we showed
was performed using anti-ET-1 antibody and anti-AQP-2 that the activation of CaR increases ET-1 mRNA tran-
antibody (Fig. 4 E and F). ET-1 signals were detected scription. These findings suggest the possibility that in-
not only in principal cells that are characterized by the creased ET-1 production in hypercalcemia is mediated
AQP-2 staining [34, 42] but also in intercalated cells. by CaR signaling.
Regulation of ET-1 promoter activity by CaR Increased expression of ET-1 protein and mRNA in
To determine whether the increased expression of ET-1 the kidney in hypercalcemia
mRNA in the renal cortex in hypercalcemic rats is due to We found that hypercalcemia increases ET-1 produc-
transcriptional activation of the ET-1 promoter through
tion in the kidney cortex but not in the medulla. In the
CaR signaling, we employed an ET-1 promoter-reporter
normal state, ET-1 is more abundant in the medulla thanassay system. COS-7 cells were transiently transfected
in the cortex [41, 45, 46] and there are no reports showingwith a luciferase reporter vector containing the 2.4 kb
kidney cortex–specific regulation of ET-1 expression.promoter region of human ET-1 and either the wild-
Since hypercalcemia causes polyuria and dehydration,type human CaR cDNA or its inactive mutant, CaRR796W.
one could speculate that dehydration may induce theCOS-7 cells were chosen because these cells are derived
increase in ET-1 expression. However, it seems unlikelyfrom kidney and have endogenous ET-1 production
because volume depletion did not alter the urinary excre-[43, 44]. Transiently transfected COS-7 cells were incu-
tion of ET-1 in humans [40]. It is more likely that hyper-bated in culture media containing various concentrations
calcemia itself stimulates ET-1 production through CaRof extracellular calcium for 48 hours, and the activity of
since we demonstrated that the activation of CaR stimu-the ET-1 promoter was measured using the luciferase
lates the transcription of ET-1. Moreover, the distribu-assay. Increasing extracellular calcium concentration
tion pattern of CaR expression may contribute to thefrom 0.5 mmol/L to 5 mmol/L significantly increased the
kidney cortex–specific induction of ET-1 expression. Inpromoter activity of ET-1 in COS-7 cells expressing the
the kidney, CaR is expressed exclusively in tubular epi-wild-type CaR, whereas extracellular calcium had no
thelial cells. Studies analyzing the distribution of CaReffect on ET-1 promoter activity in the cells expressing
mRNA by RT-PCR and in situ hybridization [47] re-CaRR796W (Fig. 5), as well as in the cells transfected with
vealed a strong signal in cortical medullary rays and acontrol vector, pcDNA3 (data not shown). These find-
less intense signal in the outer medulla. CaR mRNA isings indicate that activation of the CaR by extracellular
expressed abundantly in the CTAL, the distal convolutedcalcium indeed stimulates the transcription of the ET-1
promoter. tubule (DCT), the CCD, and modestly in the MTAL
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and the proximal straight tubule (PST). Only weak ex- One possible mechanism by which increased cortical
pression is observed in the IMCD and the proximal con- ET-1 causes polyuria is the inhibition of ENaC in CCD
voluted tubule (PCT). Immunohistochemical studies re- via activation of ETB. Recent studies that involve ETB-
vealed that CaR protein is expressed in the CTAL, the deficient rodents provided further evidence about the
MTAL, and the S1 segment of proximal tubules [48]. In important role of endothelin- ETB system on sodium
the distal tubule, only type-A intercalated cells expressed reabsorption through ENaC in vivo [25, 54]. When these
CaR. On the other hand, we demonstrated that main animals were put on a high salt diet, they easily devel-
sites for ET-1 synthesis in kidney cortex were epithelial oped hypertension, and the elevation of blood pressure
cells of tubules such as CCD and distal tubules by immu- could be prevented by the use of amiloride, a highly
nohistochmistry. These stainings seemed increased in selective ENaC inhibitor. These results suggest that en-
hypercalcemic rats. In CCD, both principal cells and dothelin-ETB system inhibits ENaC activity under physi-
intercalated cells expressed ET-1 protein. Co-localiza- ologic conditions. In addition, locally produced ET-1 in
tion of ET-1 and CaR, together with the fact that CaR kidney cortex could be transported to medulla by urine
regulates ET-1 transcription, supports the possibility that flow and may inhibit the AVP-induced water reabsorp-
CaR is responsible for the cortex-specific increase in ET-1 tion through AQP-2 in IMCD because urinary excretion
synthesis in hypercalcemia. of ET-1 was significantly increased in hypercalcemic rats.
In the current study, however, we have not addressed
Regulation of ET-1 promoter activity by CaR these issues, and further experiments are required to
Using COS-7 cells, we showed that increased extracellu- elucidate the precise role of increased ET-1 expression
lar calcium stimulates ET-1 mRNA transcription through in kidney cortex in hypercalcemia-induced polyuria.
CaR. CaR is capable of activating extracellular signal-
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